Video
:quality(75)/dvgnzpfv30f28.cloudfront.net/09-07-2020/t_c27c359049bf46f08b21487f8ae991e0_name_PORTADA_VACUNA_RUSA.jpg)
Duración: 02:13
Vacuna rusa presenta respuesta inmunitaria ante la COVID-19, según la revista The Lancet
La publicación se basa en dos pequeños estudios conducidos entre un total de 76 adultos voluntarios, entre 18 y 60 años, en buen estado de salud. Ambos, concluyeron que ninguno de los dos componentes de la vacuna provocó “efectos indeseables graves” y que su administración sucesiva “generó la producción de anticuerpos” en todos los participantes.
- Redacción Trome
- 6 de sep. de 2020 07:54 p. m.
- Duración: 02:13
PLAYLIST
:quality(75)/dvgnzpfv30f28.cloudfront.net/09-07-2020/t_c27c359049bf46f08b21487f8ae991e0_name_PORTADA_VACUNA_RUSA.jpg)
Vacuna rusa presenta respuesta inmunitaria ante la COVID-19, según la revista The Lancet
:quality(75)/cdn.jwplayer.com/v2/media/zTIslyMS/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TWUJVSAEHJHWLHC4JFXOF4N5LE.jpeg)
:quality(75)/cdn.jwplayer.com/v2/media/XngObz2M/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/3ZAFVDTS7VAGDFMZX27R7HEQNI.jpg)
Lo último en Mundo
:quality(75)/cdn.jwplayer.com/v2/media/JoqDQ3ih/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/40ImIcng/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/YC6U2Y6XSBAMNPOJCYUXCMGBKI.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/DUMKF2KCPFGBBK4XHU7HSXGNDY.png)
:quality(75)/cdn.jwplayer.com/v2/media/tAEnXvC8/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TDEMQSDUHBDFXDTG56XWHHYRTQ.png)
:quality(75)/cdn.jwplayer.com/v2/media/WaK3Fqhm/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QGQSMPOBNJBCVGTF7NPMGPXKFQ.png)
:quality(75)/cdn.jwplayer.com/v2/media/e2ILpXao/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/VCHT76KONVGCZHQYL6XG6HAVDQ.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JWJN8qew/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/2FhJXJjn/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/SCKMARUB5FFTNEECDWHJETAAOM.png)
:quality(75)/cdn.jwplayer.com/v2/media/NMgXa0xa/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/6JTKTTCGQ5EMBDWYRML3T7CS5Q.png)
:quality(75)/cdn.jwplayer.com/v2/media/w5scU31w/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/B6KkDLhn/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/mBBQZQJh/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/B5DG2M7b/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5ERQOAHLV5CD7GIVGK6BX6KLLE.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/x1pWv817/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/uLFcFqb5/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/47ZIYR5I3NHYLDYMX6HNEXHQWM.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/IgRLZjzm/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/zTIslyMS/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/TWUJVSAEHJHWLHC4JFXOF4N5LE.jpeg)
:quality(75)/cdn.jwplayer.com/v2/media/XngObz2M/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/3ZAFVDTS7VAGDFMZX27R7HEQNI.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/NXXB4Gle/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/QoxqetyX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/o1asqPX9/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eyUjAQRO/poster.jpg)